Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

Autoimmunity Reviews

Volumn 16, Issue 11, 2017, Pages 1109-1114

  Sciascia, S ^a   Coloma Bazan E ^b   Radin, M ^a   Bertolaccini, M L ^c   Lopez Pedrera C ^d   Espinosa, Gerard ^b   Meroni, P L ^e   Cervera, R ^b   Cuadrado, M J ^f  

^a UNIVERSITY OF TURIN   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e UNIVERSITY OF MILAN   (Italy)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anticoagulation; Antiphospholipid antibodies; Antiphosphospholipid syndrome; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; IMMUNOGLOBULIN A; LIPOCORTIN 5; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; THROMBOPLASTIN; TOLL LIKE RECEPTOR;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CLINICAL OUTCOME; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; HUMAN; MOLECULAR PATHOLOGY; MULTICENTER STUDY (TOPIC); OXIDATIVE STRESS; PATHOGENICITY; RECURRENT DISEASE; REVIEW; SEROCONVERSION; SYSTEMATIC REVIEW; THROMBOSIS; DRUG EFFECTS; IMMUNOLOGY; PROGNOSIS; RISK FACTOR;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; PROGNOSIS; RISK FACTORS; SEROCONVERSION; THROMBOSIS;

EID: 85030471356     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.09.004     Document Type: Review

References (55)

1. Cervera, R., Serrano, R., Pons-Estel, G.J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74 (2015), 1011–1018.
2. Ruiz-Irastorza, G., Cuadrado, M.J., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20 (2011), 206–218.
3. Radin, M., Cecchi, I., Pérez-Sánchez, C., Antiphospholipid antibodies negativization: time for testing for non-criteria aPL?. Lupus, 2017, 10.1177/0961203317711014.
4. Criado-García, J., Fernández-Puebla, R.A., López Jiménez, L., Velasco, F., Santamaría, M., Blanco-Molina, A., Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative. Rev Clin Esp 208 (2008), 135–137.
5. Medina, G., Briones-García, E., Cruz-Domínguez, M.P., Flórez-Durante, O.I., Jara, L.J., Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: thrombosis recurrence. Autoimmun Rev 16 (2017), 352–354.
6. Comarmond, C., Jego, P., Marie, I., Mekinian, A., Leroux, G., Cessation of oral anticoagulants in antiphospholipid syndrome. 2017, 1–6, 10.1177/0961203317699285.
7. Coloma Bazán, E., Donate López, C., Moreno Lozano, P., Cervera, R., Espinosa, G., Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Immunol Res 56 (2013), 358–361.
8. Cuadrado, M.J., López-Pedrera, C., Khamashta, M.A., Camps, M.T., Tinahones, F., Torres, A., et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 40 (1997), 834–841.
9. López-Pedrera, C., Buendía, P., Aguirre, M., Velasco, F., Cuadrado, M., Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus 15 (2006), 161–166.
10. Cuadrado, M.J., Buendía, P., Velasco, F., Aguirre, M.A., Barbarroja, N., Torres, L.A., et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 4 (2006), 2461–2469.
11. Dunoyer-Geindre, S., de Moerloose, P., Galve-de Rochemonteix, B., Reber, G., Kruithof, E.K.O., NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 88 (2002), 851–857.
12. Vega-Ostertag, M., Harris, E.N., Pierangeli, S.S., Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 50 (2004), 2911–2919.
13. Bohgaki, M., Atsumi, T., Yamashita, Y., Yasuda, S., Sakai, Y., Furusaki, A., et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 16 (2004), 1633–1641.
14. López-Pedrera, C., Cuadrado, M.J., Herández, V., Buendïa, P., Aguirre, M.A., Barbarroja, N., et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum 58 (2008), 2835–2844.
15. Cugno, M., Borghi, M.O., Lonati, L.M., Ghiadoni, L., Gerosa, M., Grossi, C., et al. Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 34 (2010), 105–110.
16. Ames, P.R.J., Antinolfi, I., Scenna, G., Gaeta, G., Margaglione, M., Margarita, A., Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost 7 (2009), 537–542.
17. Perez-Sanchez, C., Ruiz-Limon, P., Aguirre, M.A., Bertolaccini, M.L., Khamashta, M.A., Rodriguez-Ariza, A., et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood 119 (2012), 5859–5870.
18. Alves, J.D., Grima, B., Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep 5 (2003), 383–390.
19. Morrow, J.D., Roberts, L.J., The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 51 (1996), 1–9.
20. Iuliano, L., Praticò, D., Ferro, D., Pittoni, V., Valesini, G., Lawson, J., et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 90 (1997), 3931–3935.
21. Prinz, N., Clemens, N., Strand, D., Pütz, I., Lorenz, M., Daiber, A., et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 118 (2011), 2322–2332.
22. Raschi, E., Chighizola, C.E., Grossi, C., Ronda, N., Gatti, R., Meroni, P.L., et al. b2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two-hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun 55 (2014), 42–50.
23. Fuchs, T.A., Brill, A., Wagner, D.D., Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 32 (2012), 1777–1783.
24. Yalavarthi, S., Gould, T.J., Rao, A.N., Mazza, L.F., Morris, A.E., Núñez-Álvarez, C., et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol 67 (2015), 2990–3003.
25. Meng, H., Yalavarthi, S., Kanthi, Y., Mazza, L.F., Elfline, M.A., Luke, C.E., et al. In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis. Arthritis Rheumatol 69 (2017), 655–667.
26. Perez-Sanchez, C., Barbarroja, N., Messineo, S., Ruiz-Limon, P., Rodriguez-Ariza, A., Jimenez-Gomez, Y., et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis 74 (2015), 1441–1449.
27. Teruel, R., Pérez-Sánchez, C., Corral, J., Herranz, M.T., Pérez-Andreu, V., Saiz, E., et al. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost 9 (2011), 1985–1992.
28. Sciascia, S., Khamashta, M.A., Bertolaccini, M.L., New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Curr Rheumatol Rep, 16, 2014, 415.
29. Sciascia, S., Sanna, G., Murru, V., Roccatello, D., Khamashta, M.A., Bertolaccini, M.L., Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome a systematic review. Thromb Haemost 109 (2013), 207–213.
30. Bertolaccini, M.L., Amengual, O., Andreoli, L., Atsumi, T., Chighizola, C.B., Forastiero, R., et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13 (2014), 917–930.
31. Atsumi, T., Ieko, M., Bertolaccini, M.L., Ichikawa, K., Tsutsumi, A., Matsuura, E., et al. Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43 (2000), 1982–1993.
32. Bertolaccini, M.L., Atsumi, T., Hughes, G.R.V., Khamashta, M.A., Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinica lsignificance in systemic lupus erythematosus. Thromb Haemost 93 (2005), 289–297.
33. Tselios, K., Sarantopoulos, A., Gkougkourellas, I., Boura, P., The role of anti-phosphatidylserine/prothrombin antibodies in thrombotic manifestations of systemic lupus erythematosus patients. Front Neurol, 4, 2013, 66.
34. Sanfelippo, M., Joshi, A., Schwartz, S., Meister, J., Goldberg, J., Antibodies to phosphatidylserine/prothrombin complex in suspected antiphospholipid syndrome in the absence of antibodies to cardiolipin or beta-2-glycoprotein I. Lupus 22 (2013), 1349–1352.
35. Bertolaccini, M.L., Sciascia, S., Murru, V., Garcia-Fernandez, C., Sanna, G., Khamashta, M.A., Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. Thromb Haemost, 109, 2013.
36. de Laat, B., de Groot, P.G., Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 13 (2011), 70–76.
37. Iverson, G.M., Victoria, E.J., Marquis, D.M., Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 95 (1998), 1542–1546.
38. Reddel, S.W., Wang, Y.X., Sheng, Y.H., Krilis, S.A., Epitope studies with anti-β2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 15 (2000), 91–96.
39. De Laat, B., Derksen, R.H.W.M., Urbanus, R.T., De Groot, P.G., IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005), 1540–1545.
40. de Laat, B., Pengo, V., Pabinger, I., Musial, J., Voskuyl, A.E., Bultink, I.E.M., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7 (2009), 1767–1773.
41. Banzato, A., Pozzi, N., Frasson, R., De Filippis, V., Ruffatti, A., Bison, E., et al. Antibodies to domain I of β2Glycoprotein I are in close relation to patients' risk categories in antiphospholipid syndrome (APS). Thromb Res 128 (2011), 583–586.
42. Pericleous, C., Ferreira, I., Borghi, O., Pregnolato, F., McDonnell, T., Garza-Garcia, A., et al. Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One, 2, 2016, 11.
43. Mahler, M., Albesa, R., Zohoury, N., Bertolaccini, M.L., Rodriguez-garcia, J.L., Autoantibodies to domain 1 of beta 2 glycoprotein i determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. 2016, 911–916.
44. Andreoli, L., Nalli, C., Motta, M., Norman, G.L., Shums, Z., Encabo, S., et al. Anti-β₂-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their “innocent” profile?. Ann Rheum Dis 70 (2011), 380–383.
45. Arvieux, J., Renaudineau, Y., Mane, I., Perraut, R., Krilis, S.A., Youinou, P., Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost 87 (2002), 599–605.
46. Andreoli, L., Chighizola, C.B., Nalli, C., Gerosa, M., Borghi, M.O., Pregnolato, F., et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2-glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol 67 (2015), 2196–2204.
47. Cousins, L., Pericleous, C., Khamashta, M., Bertolaccini, M.L., Ioannou, Y., Giles, I., et al. Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome. Ann Rheum Dis 74 (2015), 317–319.
48. Bertolaccini, M.L., Atsumi, T., Escudero Contreras, A., Khamashta, M.A., Hughes, G.R., The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 28 (2001), 2637–2643.
49. Meijide, H., Sciascia, S., Sanna, G., Khamashta, M.A., Bertolaccini, M.L., The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev 12 (2013), 421–425.
50. Molina, J.F., Gutierrez-Ureña, S., Molina, J., Uribe, O., Richards, S., De Ceulaer, C., et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol 24 (1997), 291–296.
51. Diri, E., Cucurull, E., Gharavi, A.E., Kapoor, D., Mendez, E.A., Scopelitis, E., et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and aβ2 glycoprotein-I is the most frequent isotype. Lupus 8 (1999), 263–268.
52. Morales, J.M., Serrano, M., Martínez-Flores, J.A., et al. The presence of pretransplant antiphospholipid antibodies IgA anti-β-2-glycoprotein I as a predictor of graft thrombosis after renal transplantation. Transplantation 101 (2017), 597–607.
53. Sciascia, S., Radin, M., Bazzan, M., Roccatello, D., Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Intern Emerg Med 12 (2017), 1–7.
54. Conti, F., Priori, R., Alessandri, C., Misasi, R., Capozzi, A., Pendolino, M., et al. Diagnosis of catastrophic anti-phospholipid syndrome in a patient tested negative for conventional tests. Clin Exp Rheumatol, 2017 28516871.
55. Meroni, P.L., Chighizola, C.B., Rovelli, F., Gerosa, M., Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther, 16, 2014, 209.